What is Circulogene?
Circulogene operates as a specialized Liquid Biopsy Center, providing high-fidelity molecular and genomic testing designed for the comprehensive profiling of solid tumors. By integrating next-generation sequencing with sophisticated PCR technology, the company delivers actionable insights that facilitate precision oncology decisions. Their portfolio, which includes specialized diagnostic tools like LungLifeAI and OncoGenDx, serves a critical function in the clinical management of cancer patients. With a track record of supporting over 25,000 patients, Circulogene bridges the gap between complex genomic data and clinical application, ultimately aiming to optimize treatment efficacy and patient survival rates through early detection and continuous monitoring.
How much funding has Circulogene raised?
Circulogene has raised a total of $2.3M across 3 funding rounds:
Private Equity
$1.2M
Debt
$750K
Debt
$350K
Private Equity (2015): $1.2M, investors not publicly disclosed
Debt (2016): $750K, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in Circulogene
PPP
Public-Private Partnership
Undisclosed Investor
An institutional investor focused on long-term value creation through strategic equity participation in high-growth healthcare and biotech enterprises.
Undisclosed Investor
A specialized lender providing structured debt instruments to support the scaling of advanced medical technology and diagnostic service providers.
What's next for Circulogene?
With the recent infusion of capital, Circulogene is well-positioned to accelerate its research and development initiatives, particularly in the refinement of its AI-driven diagnostic platforms. The company is expected to focus on expanding its market reach, potentially scaling its laboratory infrastructure to accommodate higher testing volumes and integrating its genomic insights into broader clinical workflows. As the oncology market shifts toward more personalized, data-centric treatment paradigms, Circulogene's ability to provide longitudinal monitoring will likely serve as a key competitive advantage. Future strategic efforts will likely prioritize the validation of new biomarkers and the strengthening of partnerships with healthcare providers to standardize the use of liquid biopsies in routine cancer care.
See full Circulogene company page
